StockData
AXIM Biotechnologies, Inc. logo

AXIM Biotechnologies, Inc. (AXIM) stock

AXIMOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2024, quý kết thúc ngày Jun 30, 2024Last filing: 10-Q on Aug 19, 2024
$0.00+0.00 (+2.00%)

Close on Oct 19, 2026Market cap –P/E –Yield –

AXIM Biotechnologies, Inc. grew revenue 254.6% to $92.90K over the twelve months to Jun 30, 2024. Free cash flow was -$1.03M.

Revenue
$92.90K
+254.6% vs. a year earlier
Operating income
-$2.31M
TTM Q2 2024
Free cash flow
-$1.03M
FY2023
EPS, diluted
-$0.04
FY2023

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2024

Valuation

Market cap
–
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$92.90K
Net income
-$4.14M
EPS, diluted
-$0.04
Free cash flow
-$1.03M

Trading

Previous close
$0.00
Open
$0.00
Day's range
$0.00 – $0.00
Volume
196,278
Average volume (20 days)
148,460

Market cap history

Month-end market cap since 2014, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodAXIMS&P 500DifferenceAXIM per yearS&P 500 per year
1 month-23.5%+0.6%−24.1 pts
3 months-17.1%+3.4%−20.5 pts
Year to date-71.4%+13.3%−84.7 pts
1 year-57.5%+16.6%−74.1 pts
3 years-83.9%+86.4%−170.3 pts-45.6%+23.1%
5 years-99.3%+81.9%−181.2 pts-63.2%+12.7%
10 years-99.1%+318.9%−418.0 pts-37.7%+15.4%

Fourteen years at a glance

Fiscal years 2010 to 2023 and trailing twelve months, USD

Revenue

$92.90K+254.6% YoY

Gross profit

–

Operating income

-$2.31M

Net income

-$4.14M

EPS, diluted

–

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases AXIM Biotechnologies filed with the SEC as exhibits to Form 8-K or 6-K

About AXIM Biotechnologies

Pharmaceutical Preparations

Axim Biotechnologies, Inc. develops point-of-care diagnostic healthcare solutions focused on rapid lateral flow immunoassays. The company operates primarily in eye health diagnostics, offering FDA-cleared tear tests for dry eye disease biomarkers, including Lactoferrin and Immunoglobulin E, paired with portable digital readers. Axim also maintains diagnostic assays developed for SARS-CoV-2 neutralizing antibodies and works on additional tests for biomarkers such as MMP-9. The company provides its diagnostic systems to ophthalmologists and optometrists to assist clinicians and eye care technicians in identifying and treating ocular surface conditions.

Company profile, executives and history

AXIM Biotechnologies stock: common questions

What is AXIM Biotechnologies's stock price?

AXIM closed at $0.00 on Oct 19, 2026, up 2.00% on the day.

What is AXIM's P/E ratio?

AXIM Biotechnologies lost money over fiscal 2023 (diluted EPS -$0.04), so it has no meaningful P/E ratio.

How much revenue does AXIM Biotechnologies make?

AXIM Biotechnologies reported revenue of $92.90K for the twelve months to Jun 30, 2024, up 254.6% from a year earlier.

Does AXIM Biotechnologies pay a dividend?

No. AXIM Biotechnologies has not paid a cash dividend over the last twelve months.

How has AXIM stock performed over the past year?

Including dividends, AXIM returned -57.5% over the past year, against +16.6% for the S&P 500.

Who are AXIM Biotechnologies's competitors?

Companies most similar to AXIM Biotechnologies by business, industry and size include ALDX, REGN, HROW, OCUL, ONCO.

See a number that looks wrong?